Warning: Undefined variable $zfal in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Deprecated: str_replace(): Passing null to parameter #3 ($subject) of type array|string is deprecated in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 530
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 531
 
English Wikipedia
Nephropedia Template TP (
Twit Text
DeepDyve
Pubget Overpricing |  
lüll
Frequency and risk factors of anthracycline-induced clinical heart failure in children: a systematic review Kremer LC; van Dalen EC; Offringa M; Voute PAAnn Oncol 2002[Apr]; 13 (4): 503-12BACKGROUND: Anthracyclines are essential for the treatment of the children with cancer. We performed a systematic review to evaluate the existing evidence of the frequency and risk factors of anthracycline-induced clinical heart failure (A-CHF) in children. DESIGN: Medline was searched for articles reporting the frequency of A-CHF, published from 1966 to December 2000. Information about study features, risk factors and frequency were abstracted, and a validity score was given for each study. The potential predictive factors of A-CHF were analysed both within and across the studies. RESULTS: The frequency of A-CHF in children was estimated in 30 studies described in 25 articles. All studies have serious methodological limitations. The frequency varied between 0% and 16%. In the analysis across the studies the type of anthracyclines and the maximal dose in 1 week explain a considerable part of the variation of the frequency of A-CHF. CONCLUSIONS: Doxorubicin and a dose above 45 mg/m2 within 1 week seemed to increase the frequency of A-CHF. Well designed and executed studies are needed to accurately estimate the frequency of A-CHF and reliably assess the importance of potential risk factors.|Adolescent[MESH]|Adult[MESH]|Antibiotics, Antineoplastic/administration & dosage/*adverse effects/therapeutic use[MESH]|Cardiovascular Diseases/*chemically induced[MESH]|Child[MESH]|Child, Preschool[MESH]|Dose-Response Relationship, Drug[MESH]|Doxorubicin/administration & dosage/*adverse effects/therapeutic use[MESH]|Female[MESH]|Forecasting[MESH]|Humans[MESH]|Infant[MESH]|Infant, Newborn[MESH]|Male[MESH]|Neoplasms/drug therapy[MESH]|Risk Factors[MESH] |
